Angiogenesis is the process of new blood vessel formation from pre-existing ones. Vascular endothelial growth factor (VEGF) can induce angiogenesis and vascular leakage in the eye, which can lead to retinal diseases. The present invention relates to the use of peptides comprising tissue inhibitor of mettaloproteinases-3 (TIMP3) to substantially inhibit VEGF binding to VEGF receptor-2, while not inhibiting VEGF binding to VEGF receptor 1. This has applications for Age-Related Macular Degeneration, tumor growth, and Sorsby’s Fundus Dystrophy. Patents are issued. Peptide has been identified. Torey Hovest hovestt@ccf.org 216-445-5431
Smart, interactive desk
Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the